Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Novel oncologic therapy response criteria (iRECIST and more)

Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and prediction of treatment response.

At RSNA 2016, Mint Medical showcases a comprehensive set of new criteria including mRECIST mesothelioma, the Lugano (Cheson 2014 lymphoma) Classification, the Prostate Cancer Working Group (PCWG2) criteria, and iRECIST.

As an example, immune-related therapies can show tumor growth from treatment effect rather than true disease progression (“pseudoprogression”). mint Lesion™ 3.3 now supports the iRECIST criteria as currently drafted by the RECIST working group. iRECIST is the first immune-related criteria distinguishing between an unconfirmed and a confirmed Progressive Disease (PD).

Related Resources

Related Resources

Advancing Neuro-Oncology Assessments: Mint Medical to Integrate Newly Published RANO 2.0 Criteria into mint Lesion™

Glioblastomas and other gliomas are the most common malignant primary brain tumor types, yet few effective therapies are available. Clinical research…

WUSTL: Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations

In this retrospective study utilizing the mint Lesion™ software[1], researchers found that routine clinical interpretations frequently resulted in the…

Tumor Growth Rate Modeling: A Novel Approach to Evaluating the Efficacy of Cancer Therapies

The 2020 review of Clinical Trial Evidence Supporting US Food and Drug Administrative Approval of Novel Cancer Therapies Between 2000 and 2016…